Intratumoral Microbiota: Insights from Anatomical, Molecular, and Clinical Perspectives Original paper
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read MoreI am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.
-
Microbes
Microbes
Microbes, short for microorganisms, are tiny living organisms that are ubiquitous in the environment, including on and inside the human body. They play a crucial role in human health and disease, functioning within complex ecosystems in various parts of the body, such as the skin, mouth, gut, and respiratory tract. The human microbiome, which is […]
-
Intratumoural Microbiota
Intratumoural Microbiota
With the growing understanding of the intratumoral microbiota’s influence on cancer progression, the next frontier in cancer therapy is microbiota-targeted interventions. By introducing beneficial microbes or altering existing microbial populations within tumors, therapies can be designed to modulate the immune system, promote tumor suppression, and improve drug efficacy. However, challenges remain in deciphering the complex relationships between microbes, tumor cells, and the immune system, necessitating more refined research methods and standardized approaches to translate these discoveries into clinical practice.
-
Divine Aleru
Read More
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read More
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Divine Aleru
What was studied?
This review article explores the role of intratumoral microbiota in cancer initiation, progression, and therapeutic responses. It highlights the complex interactions between microbial communities and the tumor microenvironment (TME) in various cancers, including colorectal, breast, pancreatic, and lung cancers. The review investigates how the presence of specific microbes within tumor tissues influences carcinogenesis, immune response, and metastasis. It also discusses the impact of these microbes on cancer treatment efficacy, including chemotherapy, immunotherapy, and other targeted therapies. The study focuses on the mechanisms by which microbes promote or inhibit tumor growth, including DNA damage, inflammation, immune suppression, and oncogenic pathway activation.
Who was studied?
The article synthesizes data from clinical studies and animal models investigating the presence of microorganisms within tumor tissues. The review includes research on various cancer types, with a particular focus on gastrointestinal, breast, and pancreatic cancers. Studies examining microbial profiles in tumor biopsies and adjacent tissues are considered, along with research on the role of specific microbes, such as Fusobacterium nucleatum, Escherichia coli, and Bacteroides fragilis, in tumorigenesis. Additionally, the review looks at the influence of microbial populations on the immune response and their potential to modulate the TME to either promote or suppress tumor progression.
Most important findings
The review identifies several critical findings regarding the role of intratumoral microbiota in cancer. It demonstrates that tumor tissues, previously thought to be sterile, actually contain distinct microbial communities. These microbes can influence tumorigenesis by causing DNA damage, inducing inflammation, and modulating immune responses. For example, Fusobacterium nucleatum is associated with colorectal cancer progression through immune suppression and activation of pro-inflammatory pathways. The review also points to the role of microbes in shaping the TME, where certain bacteria promote tumor growth by enhancing immune evasion, while others contribute to therapeutic resistance. The presence of specific bacteria, such as Bacteroides fragilis and Escherichia coli, in tumors is linked to altered immune cell activity and resistance to chemotherapy. Furthermore, the article emphasizes that microbial dysbiosis, or imbalances in microbial populations, can contribute to cancer progression and may serve as a potential biomarker for early detection and prognosis.
Key implications
The findings have significant implications for cancer diagnostics, treatment, and prognosis. The presence of specific microbial signatures in tumors could serve as biomarkers for cancer detection and to predict treatment outcomes. The manipulation of intratumoral microbiota offers a promising therapeutic strategy to enhance the efficacy of cancer treatments, particularly immunotherapies. Targeting microbial populations within the TME, either through probiotics, antibiotics, or other microbiome-based therapies, could help in restoring immune function and improving patient responses to treatment. However, more research is needed to fully understand the mechanisms by which intratumoral microbiota influence tumor progression and to develop reliable clinical strategies for microbiome-based interventions in cancer therapy.
Intratumoural Microbiota
With the growing understanding of the intratumoral microbiota’s influence on cancer progression, the next frontier in cancer therapy is microbiota-targeted interventions. By introducing beneficial microbes or altering existing microbial populations within tumors, therapies can be designed to modulate the immune system, promote tumor suppression, and improve drug efficacy. However, challenges remain in deciphering the complex relationships between microbes, tumor cells, and the immune system, necessitating more refined research methods and standardized approaches to translate these discoveries into clinical practice.
Breast Cancer
Traditionally linked to genetic predispositions and environmental exposures, emerging evidence highlights the microbiome as a critical and underappreciated factor influencing breast cancer progression, immune response, and treatment outcomes.
Microbiome-Targeted Interventions (MBTIs)
Microbiome Targeted Interventions (MBTIs) are cutting-edge treatments that utilize information from Microbiome Signatures to modulate the microbiome, revolutionizing medicine with unparalleled precision and impact.